Artia Global Partners
Latest statistics and disclosures from Artia Global Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INSM, ABVX, LLY, TRVI, ARGX, and represent 59.33% of Artia Global Partners's stock portfolio.
- Added to shares of these 10 stocks: AZN (+$19M), MRNA (+$10M), ALMS (+$7.2M), MRK (+$5.6M), TERN (+$5.5M), JNJ (+$5.5M), BIIB, EWTX, RVMD, XENE.
- Started 11 new stock positions in CYTK, ELVN, TERN, APGE, ALMS, JNJ, EWTX, MRK, AZN, MRNA. BIIB.
- Reduced shares in these 10 stocks: INSM (-$32M), , ARGX (-$26M), QURE (-$25M), AstraZeneca (-$18M), VKTX (-$18M), SLNO (-$17M), CDTX (-$16M), LLY (-$11M), .
- Sold out of its positions in ALNY, ANRO, AstraZeneca, Avidity Biosciences Ord, CDTX, LYRA, OCUL, PVLA, UGL, UPB. VTYX, QURE.
- Artia Global Partners was a net seller of stock by $-159M.
- Artia Global Partners has $499M in assets under management (AUM), dropping by -29.24%.
- Central Index Key (CIK): 0001937964
Tip: Access up to 7 years of quarterly data
Positions held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Artia Global Partners
Artia Global Partners holds 49 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Insmed Com Par $.01 (INSM) | 29.7 | $149M | -17% | 908k | 163.52 |
|
| Abivax Sa Sponsored Ads (ABVX) | 13.4 | $67M | 601k | 111.35 |
|
|
| Eli Lilly & Co. (LLY) | 7.0 | $35M | -24% | 38k | 919.77 |
|
| Trevi Therapeutics (TRVI) | 4.8 | $24M | 2.0M | 11.93 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 4.3 | $22M | -54% | 30k | 730.25 |
|
| Astrazeneca Ord (AZN) | 3.8 | $19M | NEW | 95k | 197.22 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 3.2 | $16M | 504k | 32.01 |
|
|
| Dianthus Therapeutics (DNTH) | 2.7 | $14M | -20% | 163k | 83.92 |
|
| Revolution Medicines (RVMD) | 2.4 | $12M | +19% | 125k | 97.25 |
|
| Ionis Pharmaceuticals (IONS) | 2.2 | $11M | 144k | 75.09 |
|
|
| Moderna Call Option (MRNA) | 2.0 | $10M | NEW | 200k | 50.80 |
|
| Eyepoint Com New (EYPT) | 2.0 | $9.9M | 767k | 12.89 |
|
|
| Quest Diagnostics Incorporated (DGX) | 1.6 | $8.0M | 41k | 195.98 |
|
|
| Alumis (ALMS) | 1.4 | $7.2M | NEW | 325k | 22.03 |
|
| Viking Therapeutics (VKTX) | 1.2 | $5.9M | -74% | 181k | 32.54 |
|
| Merck & Co (MRK) | 1.1 | $5.6M | NEW | 47k | 120.29 |
|
| Terns Pharmaceuticals (TERN) | 1.1 | $5.5M | NEW | 105k | 52.72 |
|
| Johnson & Johnson (JNJ) | 1.1 | $5.5M | NEW | 23k | 244.44 |
|
| Sionna Therapeutics (SION) | 1.0 | $4.8M | 120k | 40.09 |
|
|
| Scholar Rock Hldg Corp (SRRK) | 0.9 | $4.7M | 96k | 49.16 |
|
|
| Rapport Therapeutics (RAPP) | 0.9 | $4.3M | 139k | 31.29 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.8 | $4.1M | 18k | 228.73 |
|
|
| Belite Bio Sponsored Ads (BLTE) | 0.8 | $4.0M | +38% | 25k | 159.44 |
|
| Xenon Pharmaceuticals (XENE) | 0.8 | $3.8M | +62% | 65k | 58.15 |
|
| Mineralys Therapeutics (MLYS) | 0.7 | $3.7M | 138k | 27.09 |
|
|
| Roivant Sciences SHS (ROIV) | 0.7 | $3.6M | 130k | 27.70 |
|
|
| Palisade Bio (PALI) | 0.7 | $3.5M | 2.0M | 1.75 |
|
|
| Biogen Idec (BIIB) | 0.7 | $3.4M | NEW | 18k | 183.33 |
|
| Prokidney Corp Shs Cl A (PROK) | 0.6 | $3.2M | 1.8M | 1.79 |
|
|
| Abbvie (ABBV) | 0.6 | $3.2M | 15k | 217.49 |
|
|
| United Therapeutics Corporation (UTHR) | 0.6 | $3.0M | 5.0k | 592.98 |
|
|
| Bright Minds Biosciences Com New (DRUG) | 0.6 | $2.8M | +14% | 38k | 72.97 |
|
| Protagonist Therapeutics (PTGX) | 0.5 | $2.4M | 23k | 105.40 |
|
|
| Soleno Therapeutics (SLNO) | 0.5 | $2.3M | -88% | 69k | 33.48 |
|
| Brightspring Health Svcs (BTSG) | 0.5 | $2.3M | +29% | 54k | 42.61 |
|
| Travere Therapeutics (TVTX) | 0.4 | $2.1M | 71k | 29.71 |
|
|
| Edgewise Therapeutics (EWTX) | 0.4 | $2.1M | NEW | 66k | 31.50 |
|
| Celcuity (CELC) | 0.4 | $1.8M | +20% | 16k | 114.14 |
|
| Bridgebio Pharma (BBIO) | 0.3 | $1.5M | 20k | 74.26 |
|
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.3 | $1.4M | 29k | 48.15 |
|
|
| Cytokinetics Com New (CYTK) | 0.2 | $1.1M | NEW | 16k | 65.91 |
|
| Enliven Therapeutics (ELVN) | 0.2 | $819k | NEW | 21k | 39.20 |
|
| Praxis Precision Medicines I Com New (PRAX) | 0.2 | $806k | 2.5k | 322.19 |
|
|
| Tenax Therapeutics Com New (TENX) | 0.1 | $673k | 42k | 15.99 |
|
|
| Kodiak Sciences (KOD) | 0.1 | $649k | 17k | 38.12 |
|
|
| Nuvalent Inc-a (NUVL) | 0.1 | $502k | -39% | 4.9k | 102.45 |
|
| Apogee Therapeutics (APGE) | 0.1 | $495k | NEW | 5.9k | 84.17 |
|
| Avalo Therapeutics Com New (AVTX) | 0.1 | $433k | -30% | 29k | 14.93 |
|
| Pepgen (PEPG) | 0.1 | $363k | 205k | 1.77 |
|
Past Filings by Artia Global Partners
SEC 13F filings are viewable for Artia Global Partners going back to 2022
- Artia Global Partners 2026 Q1 filed May 15, 2026
- Artia Global Partners 2025 Q4 filed Feb. 17, 2026
- Artia Global Partners 2025 Q3 filed Nov. 14, 2025
- Artia Global Partners 2025 Q3 restated filed Nov. 14, 2025
- Artia Global Partners 2025 Q2 filed Aug. 14, 2025
- Artia Global Partners 2025 Q1 filed May 15, 2025
- Artia Global Partners 2024 Q4 filed Feb. 14, 2025
- Artia Global Partners 2024 Q3 filed Nov. 14, 2024
- Artia Global Partners 2024 Q2 filed Aug. 14, 2024
- Artia Global Partners 2024 Q1 filed May 15, 2024
- Artia Global Partners 2023 Q4 filed Feb. 14, 2024
- Artia Global Partners 2023 Q3 filed Nov. 14, 2023
- Artia Global Partners 2023 Q2 filed Aug. 14, 2023
- Artia Global Partners 2023 Q1 filed May 15, 2023
- Artia Global Partners 2022 Q4 filed Feb. 14, 2023